The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions

M. B. Hilscher; L. J. Odell; L. J. Myhre; L. Prokop; J. Talwalkar

doi:10.1111/jcpt.12443

The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions

M. B. Hilscher, L. J. Odell, L. J. Myhre, L. Prokop, J. Talwalkar

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

Original language	English (US)
Pages (from-to)	587-591
Number of pages	5
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	41
Issue number	6
DOIs	https://doi.org/10.1111/jcpt.12443
State	Published - Dec 1 2016

Keywords

drug interaction
liver
pharmacists

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1111/jcpt.12443

Cite this

@article{f89afb50a18a4aadb16ab00f8d0ff398,

title = "The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions",

abstract = "What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.",

keywords = "drug interaction, liver, pharmacists",

author = "Hilscher, {M. B.} and Odell, {L. J.} and Myhre, {L. J.} and L. Prokop and J. Talwalkar",

note = "Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons Ltd",

year = "2016",

month = dec,

day = "1",

doi = "10.1111/jcpt.12443",

language = "English (US)",

volume = "41",

pages = "587--591",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - The pharmacotherapy of cirrhosis

T2 - concerns and proposed investigations and solutions

AU - Hilscher, M. B.

AU - Odell, L. J.

AU - Myhre, L. J.

AU - Prokop, L.

AU - Talwalkar, J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

AB - What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

KW - drug interaction

KW - liver

KW - pharmacists

UR - http://www.scopus.com/inward/record.url?scp=84992192165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992192165&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12443

DO - 10.1111/jcpt.12443

M3 - Comment/debate

C2 - 27576303

AN - SCOPUS:84992192165

SN - 0269-4727

VL - 41

SP - 587

EP - 591

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

IS - 6

ER -

The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this